1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, January 2019 (p2)

Cancer Analysis & Statistics in European Union, January 2019 (p2)

Customer Support

Talk to Ahmad

+1 718 618 4302

All regions

31-60 of about 100 reports

umbralisib

  • $ 10000
  • January 2019
  • 26 pages

Drug Overview Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Yescarta

  • $ 10000
  • January 2019
  • 19 pages

Drug Overview Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained ...

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • European Union

Revlimid

  • $ 10000
  • January 2019
  • 56 pages

Drug Overview Revlimid (lenalidomide; Celgene) is an oral thalidomide analog with antineoplastic, immunomodulatory, and anti-angiogenic properties. Studies have shown that Revlimid inhibits the growth ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • Japan

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

  • $ 22000
  • January 2019
  • 510 pages

Disease Overview Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts fo ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

polatuzumab vedotin

  • $ 10000
  • October 2018
  • 18 pages

Drug Overview Polatuzumab vedotin (Roche) is an antibody-drug conjugate (ADC) that combines a humanized immunoglobulin (Ig)-G1 monoclonal antibody (MAb) targeting human B-cell surface antigen cluster of ...

  • Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • European Union

MOR208

  • $ 10000
  • October 2018
  • 17 pages

Drug Overview MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible ...

  • Cancer
  • Lymphoma
  • Medical Biotechnology
  • European Union
  • United States

Selinexor

  • $ 10000
  • October 2018
  • 32 pages

Drug Overview Selinexor (Karyopharm Therapeutics/Ono Pharmaceutical) selectively inhibits the transport protein exportin-1 (XPO1), also called chromosome region maintenance-1. XPO1 is responsible for the ...

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • Trade

Bavencio

  • $ 10000
  • October 2018
  • 82 pages

Drug Overview Bavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Blincyto

  • $ 10000
  • October 2018
  • 25 pages

Drug Overview Blincyto (blinatumomab; Amgen/AstraZeneca/Astellas), produced in Chinese hamster ovary cells, is a bispecific T-cell engager that directs T-cells to target CD19-positive benign and malignant ...

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • European Union

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034, Pharma Intelligence

  • $ 22000
  • October 2018
  • 475 pages

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third ...

  • Cancer
  • Lymphoma
  • European Union
  • United States
  • Demand

The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

  • $ 3000
  • October 2018
  • 41 pages

Highlights: New therapies are emerging that harness the immune system to treat cancer, with the PD-1/L1 inhibitor class at the forefront Trial activity within NSCLC is particularly intense, as Opdivo ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • United States

Colorectal Cancer Forecast and Market Analysis to 2036, Pharma Intelligence

  • $ 22000
  • September 2018
  • 630 pages

Disease Overview Colorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiato ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • Demand

Seribantumab

  • $ 10000
  • August 2018
  • 16 pages

Drug Overview Seribantumab (Merrimack Pharmaceuticals) is a monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3), also known as ErbB3. HER3 is a member of the epidermal ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Lorlatinib

  • $ 10000
  • August 2018
  • 16 pages

Drug Overview Lorlatinib (Pfizer) is an orally administered anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor (TKI) with potential antineoplastic activity. Genetic alterations to ROS1 ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Entrectinib

  • $ 10000
  • August 2018
  • 15 pages

Drug Overview Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Cemiplimab

  • $ 10000
  • August 2018
  • 17 pages

Drug Overview Cemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody. The interaction between PD-1 and its ligand PD-L1 on a T cell reduces T-cell function signals, resulting ...

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • United States

Capmatinib

  • $ 10000
  • August 2018
  • 17 pages

Drug Overview Capmatinib (Incyte/Novartis) is an orally bioavailable inhibitor of the proto-oncogene c-MET, also called hepatocyte growth factor receptor (HGFR). C-MET is a receptor tyrosine kinase, and ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Alunbrig

  • $ 10000
  • August 2018
  • 16 pages

Drug Overview Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. In preclinical studies, Alunbrig showed potent activity against ...

  • Cancer
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • European Union

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035, Pharma Intelligence

  • $ 22000
  • August 2018
  • 1006 pages

Disease Overview Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancer (NSCLC), with the exact proportion depending ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Zykadia

  • $ 10000
  • August 2018
  • 19 pages

Drug Overview Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Xalkori

  • $ 10000
  • August 2018
  • 19 pages

Drug Overview Xalkori (crizotinib; Pfizer/Merck KGaA) is a selective, adenosine triphosphate-competitive small molecule multi-kinase inhibitor of mesenchymal epithelial transition growth factor (c-Met ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Vargatef

  • $ 10000
  • August 2018
  • 17 pages

Drug Overview Vargatef (nintedanib; Boehringer Ingelheim) is a triple angiokinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union

Tarceva

  • $ 10000
  • August 2018
  • 25 pages

Drug Overview Tarceva (erlotinib; Roche/Chugai/Astellas) is an orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is part of the ErbB pathway, which is hyperactivated ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Tagrisso

  • $ 10000
  • August 2018
  • 20 pages

Drug Overview Tagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR) inhibitor developed by AstraZeneca. Tagrisso has shown clinical activity against the EGFR T790M mutation, ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Tafinlar

  • $ 10000
  • August 2018
  • 33 pages

Drug Overview Tafinlar (dabrafenib; Novartis) is an adenosine triphosphate-competitive BRAF inhibitor with more than 100-fold selectivity for mutated BRAF over wild-type. BRAF is part of the mitogen-activated ...

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • United States

Portrazza

  • $ 10000
  • August 2018
  • 17 pages

Drug Overview Portrazza (necitumumab; Eli Lilly) is a recombinant IgG1 monoclonal antibody (MAb) that blocks the binding of epidermal growth factor receptor (EGFR) to its ligands. This binding prevents ...

  • Cancer
  • Lung Cancer
  • Medical Biotechnology
  • Therapy
  • European Union

Ensartinib

  • $ 10000
  • August 2018
  • 16 pages

Drug Overview Ensartinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Xcovery. In approximately 3–5% of all non-small cell lung cancer (NSCLC) patients, abnormal ALK ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Supply

Alimta

  • $ 10000
  • August 2018
  • 27 pages

Drug Overview Alimta (pemetrexed; Eli Lilly) is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. Similar to fluorouracil, ...

  • Cancer
  • European Union
  • Japan
  • United States
  • Litigation And Patent

Alecensa

  • $ 10000
  • August 2018
  • 22 pages

Drug Overview Alecensa (alectinib) is a second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Roche and Chugai. In some non-small cell lung cancer (NSCLC) patients, abnormal ALK configuration ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Supply

Abraxane

  • $ 10000
  • August 2018
  • 48 pages

Drug Overview Abraxane (nab-paclitaxel; Celgene/Taiho) is an albumin-bound formulation of paclitaxel, an antimicrotubule taxane that interferes with the growth of tumors by inhibiting mitosis during metaphase. ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on